Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Status: | Recruiting |
---|---|
Conditions: | Cancer, Cancer, Cancer, Cancer, Cancer, Infectious Disease, Infectious Disease, Lymphoma |
Therapuetic Areas: | Immunology / Infectious Diseases, Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/22/2019 |
Start Date: | April 2014 |
End Date: | July 2026 |
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
There are two study questions we are asking in this randomized phase II/III trial based on a
blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally
advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard
concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if
there is no detectable EBV DNA in their plasma, then patients are randomized to either
standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still
detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and
fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high
energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin,
fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil
is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in
treating patients with nasopharyngeal cancer.
blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally
advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard
concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if
there is no detectable EBV DNA in their plasma, then patients are randomized to either
standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still
detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and
fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high
energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin,
fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil
is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in
treating patients with nasopharyngeal cancer.
PRIMARY OBJECTIVES:
I. To determine whether substituting adjuvant concurrent high dose cisplatin (CDDP) and
fluorouracil (5-FU) with gemcitabine (gemcitabine hydrochloride) and paclitaxel will result
in superior progression-free survival. (Detectable Plasma Epstein Barr Virus [EBV]
Deoxyribonucleic Acid [DNA] Cohort randomized Phase II) II. To determine whether omitting
adjuvant CDDP and 5-FU (observation alone in the adjuvant setting) will result in
non-inferior overall survival as compared with those patients receiving adjuvant CDDP and
5-FU chemotherapy. (Undetectable Plasma EBV DNA Cohort Phase III)
SECONDARY OBJECTIVES:
I. Time to distant metastasis. (Randomized Phase II and Phase III) II. Time to local
progression. (Randomized Phase II and Phase III) III. Time to regional progression.
(Randomized Phase II and Phase III) IV. Progression-free survival (Undetectable Cohort). V.
Overall survival (Detectable Cohort). VI. Acute and late toxicity profiles based on
clinician-reported Common Terminology Criteria for Adverse Events (CTCAE), version (v.) 4.
(Randomized Phase II and Phase III) VII. Death during or within 30 days of end of protocol
treatment. (Randomized Phase II and Phase III) VIII. Quality of life (general and physical
well-being). (Randomized Phase II and Phase III) IX. Quality of life (hearing). (Randomized
Phase II and Phase III) X. Quality of life (peripheral neuropathy). (Randomized Phase II and
Phase III) XI. Cost effectiveness. (Randomized Phase II and Phase III)
OUTLINE:
Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) 5 days a week
for 6.5 weeks and receive low-dose cisplatin intravenously (IV) over 30-60 minutes once
weekly during IMRT. Beginning 1 week after chemoradiation, plasma samples are collected for
EBV DNA analysis.
PHASE II: Patients with detectable EBV DNA from pre-treatment analysis are randomized to 1 of
2 treatment arms.
ARM I: Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and
fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of
IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or
unacceptable toxicity.
ARM II: Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine
hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT.
Treatment repeats every 21 days for 4 courses in the absence of disease progression or
unacceptable toxicity.
PHASE III:
Patients with undetectable EBV DNA from pre-treatment analysis are randomized to 1 of 2
treatment arms.
ARM III: Patients receive PF regimen as in Arm I.
ARM IV: Patients undergo clinical observation.
After completion of study treatment, patients are followed up every 4 months for 2 years,
every 6 months for 3 years, and then annually thereafter.
I. To determine whether substituting adjuvant concurrent high dose cisplatin (CDDP) and
fluorouracil (5-FU) with gemcitabine (gemcitabine hydrochloride) and paclitaxel will result
in superior progression-free survival. (Detectable Plasma Epstein Barr Virus [EBV]
Deoxyribonucleic Acid [DNA] Cohort randomized Phase II) II. To determine whether omitting
adjuvant CDDP and 5-FU (observation alone in the adjuvant setting) will result in
non-inferior overall survival as compared with those patients receiving adjuvant CDDP and
5-FU chemotherapy. (Undetectable Plasma EBV DNA Cohort Phase III)
SECONDARY OBJECTIVES:
I. Time to distant metastasis. (Randomized Phase II and Phase III) II. Time to local
progression. (Randomized Phase II and Phase III) III. Time to regional progression.
(Randomized Phase II and Phase III) IV. Progression-free survival (Undetectable Cohort). V.
Overall survival (Detectable Cohort). VI. Acute and late toxicity profiles based on
clinician-reported Common Terminology Criteria for Adverse Events (CTCAE), version (v.) 4.
(Randomized Phase II and Phase III) VII. Death during or within 30 days of end of protocol
treatment. (Randomized Phase II and Phase III) VIII. Quality of life (general and physical
well-being). (Randomized Phase II and Phase III) IX. Quality of life (hearing). (Randomized
Phase II and Phase III) X. Quality of life (peripheral neuropathy). (Randomized Phase II and
Phase III) XI. Cost effectiveness. (Randomized Phase II and Phase III)
OUTLINE:
Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) 5 days a week
for 6.5 weeks and receive low-dose cisplatin intravenously (IV) over 30-60 minutes once
weekly during IMRT. Beginning 1 week after chemoradiation, plasma samples are collected for
EBV DNA analysis.
PHASE II: Patients with detectable EBV DNA from pre-treatment analysis are randomized to 1 of
2 treatment arms.
ARM I: Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and
fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of
IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or
unacceptable toxicity.
ARM II: Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine
hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT.
Treatment repeats every 21 days for 4 courses in the absence of disease progression or
unacceptable toxicity.
PHASE III:
Patients with undetectable EBV DNA from pre-treatment analysis are randomized to 1 of 2
treatment arms.
ARM III: Patients receive PF regimen as in Arm I.
ARM IV: Patients undergo clinical observation.
After completion of study treatment, patients are followed up every 4 months for 2 years,
every 6 months for 3 years, and then annually thereafter.
Inclusion Criteria:
- Biopsy proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the
nasopharynx
- Patients must have detectable pretreatment plasma EBV DNA, determined by the central
lab prior to Step 2 registration
- Stage II-IVB disease (American Joint Committee on Cancer [AJCC], 7th edition [ed.])
with no evidence of distant metastasis, based upon the following minimum diagnostic
workup:
- History/physical examination by a Medical Oncologist or Clinical Oncologist or
Radiation Oncologist or Ear, Nose, Throat specialist (ENT), which must include an
endoscopic evaluation, a complete list of current medications, and assessment of
weight and weight loss in the past 6 months within 21 days prior to registration
- Evaluation of tumor extent with magnetic resonance imaging (MRI) of the
nasopharynx and neck within 28 days prior to registration; if MRI is medically
contraindicated, obtain computed tomography (CT) scan with =< 3 mm contiguous
slices with contrast and bone windows (to evaluate base of skull involvement);
Note: If a treatment planning CT scan is used, it must be with =< 3 mm contiguous
slices with contrast and be read by a radiologist
- To rule out distant metastasis, patients must undergo the following imaging
within 28 days prior to registration:
- A CT scan with contrast of the chest, abdomen, and/or pelvis or a total body
positron emission tomography (PET)/CT scan (non-contrast PET/CT is
acceptable)
- A bone scan only when there is suspicion of bone metastases (a PET/CT scan
can substitute for the bone scan)
- Zubrod performance status 0-1 within 21 days prior to registration
- Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
- Platelets >= 100,000 cells/mm^3
- Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x
institutional ULN
- Alkaline phosphatase =< 1.5 x institutional ULN
- Serum creatinine =< 1.5 mg/dl or calculated creatinine clearance (CC) >= 50 ml/min
determined by 24-hour urine collection or estimated by Cockcroft-Gault formula
- Negative serum pregnancy test within 14 days prior to registration for women of
childbearing potential
- Women of childbearing potential and male participants who are sexually active must
agree to use a medically effective means of birth control throughout protocol
treatment
- Patient must provide study specific informed consent prior to study entry, including
the mandatory pre-treatment plasma EBV DNA assay
Exclusion Criteria:
- Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless
disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of
the breast, oral cavity, or cervix are all permissible)
- Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
different cancer is allowable; however, at least 6-weeks recovery is necessary if the
last regimen included nitrosourea or mitomycin
- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields
- Patients with hearing loss assessed to be primarily sensorineural in nature, requiring
a hearing aid, or intervention (i.e. interfering in a clinically significant way with
activities of daily living); a conductive hearing loss that is tumor-related is
allowed
- >= Grade 2 peripheral sensory neuropathy (CTCAE, v. 4.0)
- Severe, active co-morbidity, defined as follows:
- Major medical or psychiatric illness, which in the investigator's opinion would
interfere with the completion of therapy and follow up or with full understanding
of the risks and potential complications of the therapy
- Unstable angina and/or uncontrolled congestive heart failure within the past 6
months
- Myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time
of registration; note that patients switched from IV antibiotics and currently on
oral antibiotics whose infection is assessed to be adequately treated or
controlled are eligible
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization or precluding study therapy within 30 days prior to
registration
- Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
Control and Prevention (CDC) definition; note, however, that human
immunodeficiency virus (HIV) testing is not required for entry into this protocol
- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception
- Prior allergic reaction to the study drug(s) involved in this protocol
- Patients with undetectable pre-treatment plasma EBV DNA
We found this trial at
143
sites
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Francis P. Worden
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: Robert E. Martell
Phone: 617-636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
Duarte, California 91010
(626) 256-4673
Principal Investigator: Nayana L. Vora
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Yuhchyau Chen
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Kenneth N. Sumida
Phone: 808-678-9000
Click here to add this to my saved trials
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
American Fork, Utah 84003
Principal Investigator: Vilija N. Avizonis
Phone: 801-855-4100
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Jonathan J. Beitler
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Jonathan J. Beitler
Phone: 404-778-1868
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Jonathan J. Beitler
Phone: 412-339-5294
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Ana P. Kiess
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Mei Tang
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
Principal Investigator: Nancy Y. Lee
Phone: 212-639-5007
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Sharon A. Spencer
Phone: 205-934-0220
Click here to add this to my saved trials
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Minh T. Truong
Phone: 617-638-8265
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Annie W. Chan
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Madhur K. Garg
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Madhur K. Garg
Phone: 718-379-6866
Click here to add this to my saved trials
4802 10th Ave
Brooklyn, New York 11219
Brooklyn, New York 11219
(718) 283-6000
Principal Investigator: Jay S. Cooper
Phone: 718-765-2500
Maimonides Medical Center At 103 years old, Maimonides Medical Center remains a vital and thriving...
Click here to add this to my saved trials
263 7th Avenue
Brooklyn, New York 11215
Brooklyn, New York 11215
Principal Investigator: Krishnamurthi Sundaram
Phone: 718-780-3677
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Eleanor M. Walker
Phone: 412-339-5294
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Burlingame, California 94010
Principal Investigator: Christopher U. Jones
Phone: 650-696-4487
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
Chadds Ford, Pennsylvania 19317
Principal Investigator: Gregory A. Masters
Phone: 302-733-6227
Click here to add this to my saved trials
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Bharat B. Mittal
Phone: 312-695-1301
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 864-6000
Principal Investigator: Thomas E. Lad
Phone: 312-864-5204
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Jordan Kharofa
Phone: 513-558-4553
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: David J. Adelstein
Phone: 866-223-8100
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: David J. Adelstein
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Min Yao
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
Clinton Township, Michigan 48038
Principal Investigator: Eleanor M. Walker
Phone: 313-916-1784
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Dukagjin M. Blakaj
Phone: 800-293-5066
Click here to add this to my saved trials
Commack, New York 11725
Principal Investigator: Nancy Y. Lee
Phone: 631-623-4000
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Creve Coeur, Missouri 63141
Principal Investigator: Douglas R. Adkins
Phone: 800-600-3606
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: David J. Sher
Phone: 214-648-7097
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Anand Mahadevan
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Eleanor M. Walker
Phone: 313-916-1784
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
Click here to add this to my saved trials
Fresno, California 93720
Principal Investigator: Samantha A. Seaward
Phone: 877-642-4691
Click here to add this to my saved trials
1801 16th St
Greeley, Colorado 80631
Greeley, Colorado 80631
(970) 352-4121
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
North Colorado Medical Center NCMC is a fully accredited, private, non-profit facility licensed to operate...
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Greenville, South Carolina 29607
Principal Investigator: Robert D. Siegel
Phone: 864-603-6213
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Greer, South Carolina 29651
Principal Investigator: Patricia C. Griffin
Phone: 864-560-6104
Click here to add this to my saved trials
24800 SE Stark St
Gresham, Oregon 97030
Gresham, Oregon 97030
(503) 674-1122
Principal Investigator: Andrew Y. Kee
Phone: 503-413-2150
Legacy Mount Hood Medical Center Legacy Mount Hood Medical Center, East County's full-service community hospital,...
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Harrison, New York 10604
Principal Investigator: Nancy Y. Lee
Phone: 212-639-7592
Click here to add this to my saved trials
Honolulu, Hawaii 96817
Principal Investigator: Kenneth N. Sumida
Phone: 808-547-6881
Click here to add this to my saved trials
1301 Punchbowl St
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
(808) 538-9011
Principal Investigator: Kenneth N. Sumida
Phone: 412-339-5294
Queen's Medical Center The Queen's Medical Center, located in downtown Honolulu, Hawaii, is a private,...
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Carryn M. Anderson
Phone: 800-237-1225
Click here to add this to my saved trials
La Crosse, Wisconsin
Principal Investigator: Collin D. Driscoll
Phone: 608-775-2385
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
La Jolla, California 92093
(858) 822-6100
Principal Investigator: Loren K. Mell
Phone: 858-822-5354
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
Click here to add this to my saved trials
Lewisburg, Pennsylvania 17837
Principal Investigator: Anand Mahadevan
Phone: 570-374-8555
Click here to add this to my saved trials
Livonia, Michigan 48154
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
2000 N Boise Ave
Loveland, Colorado 80538
Loveland, Colorado 80538
(970) 669-4640
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
McKee Medical Center Through the years, McKee has led the way in health care innovation....
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Paul M. Harari
Phone: 800-622-8922
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
Click here to add this to my saved trials
Mansfield, Ohio 44906
Principal Investigator: David J. Adelstein
Phone: 866-223-8100
Click here to add this to my saved trials
1000 North Oak Avenue
Marshfield, Wisconsin 54449
Marshfield, Wisconsin 54449
Principal Investigator: Michael Husak
Phone: 800-782-8581
Click here to add this to my saved trials
Click here to add this to my saved trials
Middletown, New Jersey 07748
Principal Investigator: Nancy Y. Lee
Phone: 212-639-7592
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
Milwaukee, Wisconsin 53226
(414) 805-3666
Principal Investigator: Christopher J. Schultz
Phone: 414-805-4380
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
Click here to add this to my saved trials
9601 Townline Rd
Minocqua, Wisconsin 54548
Minocqua, Wisconsin 54548
(715) 358-1000
Principal Investigator: Michael Husak
Phone: 800-782-8581
Marshfield Clinic Minocqua Center The Clinic was incorporated under Wisconsin law in 1916 and operates...
Click here to add this to my saved trials
1700 Coffee Rd
Modesto, California 95355
Modesto, California 95355
(209) 526-4500
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Memorial Medical Center Memorial is affiliated with Sutter Health, a family of not-for-profit hospitals, physician...
Click here to add this to my saved trials
5121 S Cottonwood St
Murray, Utah 84157
Murray, Utah 84157
(801) 507-7000
Principal Investigator: Vilija N. Avizonis
Phone: 801-507-3950
Intermountain Medical Center Intermountain Medical Center is one of the most technologically advanced and patient-friendly...
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Henry S. Park
Phone: 203-785-5702
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Nancy Y. Lee
Phone: 212-639-7592
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Kenneth S. Hu
Phone: 212-263-4434
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Matthen Mathew
Phone: 212-305-6361
Click here to add this to my saved trials
Newark, Delaware 19713
Principal Investigator: Gregory A. Masters
Phone: 302-733-6227
Click here to add this to my saved trials
4755 Ogletown-Stanton Road
Newark, Delaware 19718
Newark, Delaware 19718
302-733-1000
Principal Investigator: Gregory A. Masters
Phone: 302-733-6227
Christiana Care Health System - Christiana Hospital A 913-bed, 1.3-million-square-foot, modern facility in Newark, Delaware,...
Click here to add this to my saved trials
Oakland, California 94611
Principal Investigator: Samantha A. Seaward
Phone: 877-642-4691
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: J. S. Thompson
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73120
Principal Investigator: Jay W. Carlson
Phone: 405-752-3402
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
Omaha, Nebraska 68114
(402) 354–4000
Principal Investigator: Tien-Shew W. Huang
Phone: 402-354-5144
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
Click here to add this to my saved trials
Orange, California 92868
Principal Investigator: Samuel Ejadi
Phone: 877-827-8839
Click here to add this to my saved trials
Palo Alto, California 94301
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
875 Blake Wilbur Drive
Palo Alto, California 94304
Palo Alto, California 94304
Principal Investigator: Quynh-Thu X. Le
Phone: 650-498-7061
Click here to add this to my saved trials
Parker Adventist Hospital When Parker Adventist Hospital opened in 2004, it set a new standard...
Click here to add this to my saved trials
Pontiac, Michigan 48341
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
1015 NW 22nd Ave
Portland, Oregon 97210
Portland, Oregon 97210
(503) 413-7711
Principal Investigator: Andrew Y. Kee
Phone: 800-220-4937
Legacy Good Samaritan Hospital and Medical Center Located in the heart of Northwest Portland, Legacy...
Click here to add this to my saved trials
Rancho Cordova, California 95670
Principal Investigator: Samantha A. Seaward
Phone: 877-642-4691
Click here to add this to my saved trials
Reno, Nevada 89502
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Reno, Nevada 89503
Principal Investigator: John A. Ellerton
Phone: 412-339-5294
Click here to add this to my saved trials
1700 W Stout St
Rice Lake, Wisconsin 54868
Rice Lake, Wisconsin 54868
(715) 236-8100
Principal Investigator: Michael Husak
Phone: 800-782-8581
Marshfield Clinic Rice Lake Center The Clinic was incorporated under Wisconsin law in 1916 and...
Click here to add this to my saved trials
Riverton, Utah 84065
Principal Investigator: Vilija N. Avizonis
Phone: 801-507-3950
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Robert L. Foote
Phone: 855-776-0015
Click here to add this to my saved trials
Rockville Centre, New York 11570
Principal Investigator: Nancy Y. Lee
Phone: 516-256-3651
Click here to add this to my saved trials
Rohnert Park, California 94928
Principal Investigator: Samantha A. Seaward
Phone: 877-642-4691
Click here to add this to my saved trials
Rolla, Missouri 65401
Principal Investigator: Jay W. Carlson
Phone: 573-458-7504
Click here to add this to my saved trials